A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

ClinicalTrials.gov ID: NCT05118789

Public ClinicalTrials.gov record NCT05118789. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 6, 2026, 8:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors (ARROS-1)

Study identification

NCT ID: NCT05118789
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Nuvalent Inc.; Industry
Enrollment: 359 participants

Conditions and interventions

Conditions

Interventions

Zidesamtinib (NVL-520) Drug

Drug

Eligibility (public fields only)

Age range: 12 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 3, 2022
Primary completion: Dec 30, 2027
Completion: Dec 30, 2028
Last update posted: Oct 23, 2025

2022 – 2028

United States locations

U.S. sites: 20
U.S. states: 16
U.S. cities: 18

Facility	City	State	ZIP	Site status
UCI Medical Center	Orange	California	92868	Recruiting
Stanford Medicine	Palo Alto	California	94305	Recruiting
UC Davis Comprehensive Cancer Center	Sacramento	California	95817	Recruiting
University of Colorado Cancer Center	Denver	Colorado	80045	Recruiting
Georgetown University Medical Center	Washington D.C.	District of Columbia	20007	Recruiting
University of Miami	Coral Gables	Florida	33146	Recruiting
University of Chicago	Chicago	Illinois	60637	Recruiting
Mass General Hospital	Boston	Massachusetts	02114	Recruiting
Dana-Farber Cancer Institute	Boston	Massachusetts	02215	Recruiting
Henry Ford Cancer Institute	Detroit	Michigan	48202	Recruiting
Washington University School of Medicine	St Louis	Missouri	63110	Recruiting
NYU Langone Health	New York	New York	10016	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Recruiting
Atrium Health Levine Cancer Institute	Charlotte	North Carolina	28204	Recruiting
Ohio State University	Columbus	Ohio	43210	Recruiting
Fox Chase Cancer Center	Philadelphia	Pennsylvania	19111	Recruiting
Sarah Cannon Research Institute	Nashville	Tennessee	37203	Recruiting
MD Anderson Cancer Center	Houston	Texas	77030	Active, not recruiting
NEXT Oncology - Virginia Cancer Specialists	Fairfax	Virginia	22031	Recruiting
University of Washington / Fred Hutchinson Cancer Center	Seattle	Washington	98109	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 43 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05118789, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 23, 2025 · Synced May 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05118789 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →